docetaxel anhydrous has been researched along with fluorodeoxyglucose f18 in 45 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (fluorodeoxyglucose f18) | Trials (fluorodeoxyglucose f18) | Recent Studies (post-2010) (fluorodeoxyglucose f18) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 34,771 | 2,160 | 20,111 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (15.56) | 29.6817 |
| 2010's | 35 (77.78) | 24.3611 |
| 2020's | 3 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ah-See, AK; Chilcott, F; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Payne, S; Sharp, PF; Smith, IC; Waikar, S; Welch, AE; Whitaker, T | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Chao, KS | 1 |
| Hanna, WT; Hubner, KF; Long, MJ; Nahmias, C; Townsend, DW; Wahl, LM | 1 |
| Coleman, RL; Gershenson, DM; Han, LY; Jennings, N; Kamat, AA; Kim, TJ; Kundra, V; Landen, CN; Langley, R; Lin, YG; Lu, C; Merritt, WM; Ravoori, M; Sood, AK; Spannuth, WA | 1 |
| Katz, JK; Sharma, R | 1 |
| Kubo, A; Mitsui, Y; Nakahara, T; Shigematsu, N; Takagi, Y; Takemasa, K; Tsuyuki, A | 1 |
| Jung, SY; Kang, HS; Kim, EA; Kim, SK; Kim, SW; Ko, KL; Kwon, Y; Lee, KS; Lee, S; Lee, SJ; Min, SY; Nam, BH; Park, C; Park, IH; Ro, J; Shin, KH | 1 |
| Anand, A; Dzik-Jurasz, A; Hu, J; Rathkopf, D; Ross, RW; Scher, HI; Tanaka, E; Wong, BY; Woo, MM; Yang, W | 1 |
| Fox, J; Ganju, V; Hart, S; Hofman, M; Midolo, P; Schneider-Kolsky, ME; Stuckey, J | 1 |
| Eary, JF; Hackenbracht, JA; Higano, CS; Link, JM; Mankoff, DA; Montgomery, RB; Muzi, M; Rezvani, BB; Yu, EY | 1 |
| Bluemke, DA; Gabrielson, E; Jacobs, MA; Jeter, S; Ouwerkerk, R; Stearns, V; Wahl, R; Warzecha, H; Wolff, AC | 1 |
| Abel, U; Debus, J; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lorenzen, S; Münter, MW; Stange, A; von Gall, C; Weichert, W; Weitz, J | 1 |
| Helin, H; Karhumäki, L; Kauppi, JT; Kemppainen, J; Oksala, N; Räsänen, JV; Salo, JA; Sihvo, EI | 1 |
| Bang, YJ; Cho, N; Chung, JK; Han, SW; Han, W; Im, SA; Kang, KW; Keam, B; Kim, JH; Kim, TY; Koh, Y; Moon, WK; Noh, DY; Oh, DY; Park, IA | 1 |
| Altabef, A; Bardeesy, N; Butaney, M; Cameron, MD; Cantley, LC; Castrillon, DH; Chen, Z; Cheng, K; Chirieac, LR; Costa, DB; Demetri, GD; Ebi, H; Engelman, JA; Franchetti, Y; Gao, P; Hayes, DN; Jackman, D; Jänne, PA; Kung, AL; Lee, C; Lee, CB; Li, J; Liu, Y; Nakada, Y; Nishino, M; Ouyang, J; Pandolfi, PP; Peña, CG; Roberts, PJ; Saur, A; Sharpless, NE; Shimamura, T; Sun, Y; Tupper, T; Walton, Z; Wang, S; Wang, Y; Wilkerson, MD; Wong, KK; Woo, MS; Xu, C; Yanagita, M; Yao, C | 1 |
| Buonerba, C; D'Aniello, C; Damiano, V; De Placido, S; Di Lorenzo, G; Di Trolio, R; Federico, P; Mainolfi, C; Matano, E; Palmieri, G; Raimondo, L; Rescigno, P | 1 |
| Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK | 1 |
| Abgral, R; Gouders, D; Keromnes, N; Le Roux, PY; Leleu, C; Mollon, D; Nowak, E; Querellou, S; Rousset, J; Salaün, PY; Valette, G | 1 |
| Enoki, Y; Fujimoto, S; Fukui, A; Morishita, H; Okuyama, Y; Yoshida, N | 1 |
| Coussy, F; Cuvier, C; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hatt, M; Hindié, E; Marty, M; Vercellino, L | 1 |
| Bassini, A; Bertola, M; Del Conte, A; Foltran, L; Gion, M; Lorenzon, M; Micheli, E; Saracchini, S; Sulfaro, S; Tuccia, F; Tumolo, S | 1 |
| Fushiki, H; Jitsuoka, M; Matsunari, I; Mitsuoka, K; Miyoshi, S; Murakami, Y; Nishimura, S; Noda, A; Sasaki, H | 1 |
| Akiyoshi, T; Fujii, T; Fujisawa, T; Hirakata, T; Horikoshi, H; Iijima, M; Kinoshita, T; Kuwano, H; Miyamoto, T; Oya, N; Yanagita, Y | 1 |
| Berger, F; de Cremoux, P; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hamy, AS; Hatt, M; Hindié, E; Marty, M; Merlet, P | 1 |
| Boirie, Y; Chadeyras, JB; Coudert, B; Durando, X; Gadea, E; Kwiatkowski, F; Merlin, C; Morio, B; Paulon, R; Thivat, E | 1 |
| Bijnsdorp, IV; Geldof, AA; Hoekstra, OS; Oprea-Lager, DE; van de Ven, PM; van den Eertwegh, AJ; van Kanten, MP; van Moorselaar, RJ | 1 |
| Barjat, H; Ehrlichmann, W; Honndorf, VS; Pichler, BJ; Quintanilla-Martinez, L; Ricketts, SA; Schmidt, H; Wehrl, HF; Wiehr, S | 1 |
| Beer, TM; Courtney, KD; Elfiky, AA; Kantoff, P; Loda, M; Manola, JB; Oh, WK; Priolo, C; Ross, R; Ryan, CW; Taplin, ME; Van den Abbeele, AD; Yap, JT | 1 |
| Arnould, L; Bachelot, T; Berriolo-Riedinger, A; Bougnoux, P; Coeffic, D; Coudert, B; Coudert, M; Dupré, PF; Ferrero, JM; Gabelle, P; Giard, S; Hernandez, J; Kerbrat, P; Kerrou, K; Mouret-Reynier, MA; Paintaud, G; Petit, T; Pierga, JY; Prevost, JB; Thibault, G | 1 |
| Dank, M; Györke, T; Kajáry, K; Kulka, J; Lengyel, Z; Molnár, BÁ; Szentmártoni, G; Tőkés, AM; Tőkés, T; Torgyík, L | 1 |
| Hasebe, T; Hirokawa, E; Kuji, I; Matsuura, K; Osaki, A; Saeki, T; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S; Yamane, T | 1 |
| Barjat, H; Emmas, SA; Honndorf, VS; Pichler, BJ; Quintanilla-Martinez, L; Schmidt, H; Stahlschmidt, A; Wehrl, HF; Wiehr, S | 1 |
| Baba, H; Baba, Y; Harada, K; Higashi, T; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Izumi, D; Kosumi, K; Miyamoto, Y; Miyata, T; Sakamoto, Y; Shiraishi, S; Taki, K; Tokunaga, R; Watanabe, M; Yamashita, Y; Yoshida, N | 1 |
| Hara, K; Honjo, H; Kuwano, H; Miyazaki, T; Ozawa, D; Sakai, M; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T | 1 |
| Cheon, GJ; Chung, JK; Kang, KW; Kim, EE; Kim, YI; Lee, DS; Moon, WK; Paeng, JC; Yoon, HJ | 1 |
| Kajiwara, M; Moriyama, H; Yonehara, S | 1 |
| Deák, P; Fábián, G; Kahán, Z; Kovács, L; Mózes, P; Nagy, O; Pál, M; Reisz, Z; Rovó, L; Rusz, O; Szilágyi, É; Tiszlavicz, L; Tomisa, B; Varga, Z | 1 |
| Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V | 1 |
| Bektasoglu, HK; Erdogan, EB; Ersoy, YE; Gucin, Z; Guzel, M; Kadioglu, H; Malya, FU; Yildiz, S; Yucel, S | 1 |
| Carter, BW; Goense, L; Ho, L; Hofstetter, WL; Lin, SH; Maru, DM; Meijer, GJ; van Hillegersberg, R; van Rossum, PSN; Xi, M | 1 |
| Agaimy, A; Fietkau, R; Haderlein, M; Hecht, M; Iro, H; Kitzsteiner, C; Kuwert, T; Müller, S; Schmidt, D; Semrau, S; Traxdorf, M | 1 |
| Hoshina, H; Takei, H | 1 |
| Barres, B; Chanchou, M; Coudert, B; Durando, X; Gadéa, E; Ginzac, A; Merlin, C; Molnar, I; Thivat, E | 1 |
| Brizel, DM; Choudhury, KR; Das, S; Mowery, YM; Niedzwiecki, D; Rushing, CN; Vergalasova, I; Wong, TZ; Wu, Q; Yoo, DS | 1 |
2 review(s) available for docetaxel anhydrous and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aortitis; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Female; Fever; Filgrastim; Fluorodeoxyglucose F18; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Positron Emission Tomography Computed Tomography; Trastuzumab | 2019 |
14 trial(s) available for docetaxel anhydrous and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Topics: Acetylation; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Panobinostat; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Topics: Acetates; Bone Neoplasms; Carbon; Docetaxel; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Radiography; Radiopharmaceuticals; Sodium Isotopes; Taxoids; Treatment Outcome | 2011 |
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Grading; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Phosphorylcholine; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Taxoids | 2012 |
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorodeoxyglucose F18; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Squamous Cell Carcinoma of Head and Neck; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polyethylene Glycols; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2013 |
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Everolimus; Fluorodeoxyglucose F18; Humans; Male; Maximum Tolerated Dose; Middle Aged; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER):
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2014 |
Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Treatment Outcome | 2015 |
A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients.
Topics: Adipose Tissue, Brown; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Trastuzumab; Treatment Outcome; Weight Gain | 2020 |
Early
Topics: Analysis of Variance; Antineoplastic Agents; Cisplatin; Docetaxel; Female; Fluorodeoxyglucose F18; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oropharyngeal Neoplasms; Papillomavirus Infections; Positron Emission Tomography Computed Tomography; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Treatment Outcome; Tumor Burden | 2020 |
29 other study(ies) available for docetaxel anhydrous and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prednisolone; Radiopharmaceuticals; Sensitivity and Specificity; Taxoids; Tomography, Emission-Computed; Vincristine | 2000 |
3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Forecasting; Humans; Mice; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome | 2007 |
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Female; Fluorodeoxyglucose F18; G2 Phase; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Serine; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Taxotere chemosensitivity evaluation in mice prostate tumor: validation and diagnostic accuracy of quantitative measurement of tumor characteristics by MRI, PET, and histology of mice tumor.
Topics: Animals; Antineoplastic Agents; Docetaxel; Fluorodeoxyglucose F18; Magnetic Resonance Imaging; Male; Mice; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids | 2008 |
Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis.
Topics: Acute Disease; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Fluorodeoxyglucose F18; Hepatitis; Humans; Liver; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiation Injuries; Radiopharmaceuticals; Taxoids | 2008 |
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Taxoids; Treatment Outcome | 2011 |
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2012 |
Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sentinel Lymph Node Biopsy; Taxoids; Tomography, X-Ray Computed | 2013 |
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Disease Models, Animal; Docetaxel; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Genes, p53; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Pharmacogenetics; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Reproducibility of Results; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Combination of docetaxel and cetuximab for penile cancer: a case report and literature review.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Docetaxel; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Male; Penile Neoplasms; Positron-Emission Tomography; Taxoids; Treatment Outcome | 2012 |
A large cell neuroendocrine carcinoma of the gall bladder: diagnosis with 18FDG-PET/CT-guided biliary cytology and treatment with combined chemotherapy achieved a long-term stable condition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Disseminated Intravascular Coagulation; Docetaxel; Fatal Outcome; Fluorodeoxyglucose F18; Gallbladder Neoplasms; Humans; Immunohistochemistry; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Treatment Failure | 2013 |
HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Docetaxel; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Tumor Burden; Tumor Cells, Cultured | 2013 |
Early predictive value of non-response to docetaxel in neoadjuvant chemotherapy in breast cancer using 18F-FDG-PET.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Taxoids | 2014 |
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Brown adipose tissue activity in relation to weight gain during chemotherapy in breast cancer patients: a pilot study.
Topics: Adipose Tissue, Brown; Adult; Antibodies, Monoclonal, Humanized; Body Mass Index; Breast Neoplasms; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Pilot Projects; Positron-Emission Tomography; Taxoids; Tomography, X-Ray Computed; Trastuzumab; Weight Gain | 2014 |
[18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Choline; Docetaxel; Drug Screening Assays, Antitumor; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Rhodamines; Taxoids | 2015 |
Quantitative correlation at the molecular level of tumor response to docetaxel by multimodal diffusion-weighted magnetic resonance imaging and [¹⁸F]FDG/[¹⁸F]FLT positron emission tomography.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Dideoxynucleosides; Diffusion Magnetic Resonance Imaging; Docetaxel; Female; Fluorodeoxyglucose F18; HCT116 Cells; Humans; Mice; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cross-Sectional Studies; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Sensitivity and Specificity; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2015 |
The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Proliferation; Colorectal Neoplasms; Dideoxynucleosides; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Synergism; Fluorodeoxyglucose F18; HCT116 Cells; Humans; Immunohistochemistry; Mice; Positron-Emission Tomography; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Coordination Complexes; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Taxoids | 2016 |
[Primary Squamous Cell Carcinoma of the Prostate in which Docetaxel Therapy was Effective : A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms; Taxoids | 2016 |
The Expression of Checkpoint and DNA Repair Genes in Head and Neck Cancer as Possible Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; DNA Damage; DNA Repair; Docetaxel; Down-Regulation; Female; Fluorodeoxyglucose F18; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Radiotherapy Dosage; Squamous Cell Carcinoma of Head and Neck; Taxoids; Up-Regulation | 2017 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid | 2017 |
The role of PET and MRI in evaluating the feasibility of skin-sparing mastectomy following neoadjuvant therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Taxoids | 2018 |
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Nomograms; Oxaliplatin; Positron Emission Tomography Computed Tomography; Preoperative Period; Radiopharmaceuticals; Radiotherapy Dosage; Risk Assessment; Sex Factors; Survival Rate | 2018 |
Classification of three prognostically different groups of head and neck cancer patients based on their metabolic response to induction chemotherapy (IC-1).
Topics: Adult; Aged; Carboplatin; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Patient Selection; Positron Emission Tomography Computed Tomography; Retrospective Studies; Surgical Procedures, Operative; Survival Analysis; Treatment Outcome | 2020 |